Sun X, Wang D, Chang S, Yin L, Zhang H, Ji S
Int J Nanomedicine. 2025; 20:2395-2409.
PMID: 40027874
PMC: 11871924.
DOI: 10.2147/IJN.S502257.
Li J, Shi C, Chen J, Zhao Y, Du J, Song J
J Hepatocell Carcinoma. 2025; 12:289-299.
PMID: 39991513
PMC: 11844194.
DOI: 10.2147/JHC.S494668.
Wu Y, Zhu J, Zhang H, Xia N
Cancer Manag Res. 2025; 17:239-247.
PMID: 39931267
PMC: 11809358.
DOI: 10.2147/CMAR.S481242.
Li X, Cao K, Fu Z, Chen X, Zhong J, Liu L
J Hepatocell Carcinoma. 2025; 12:169-182.
PMID: 39881676
PMC: 11776929.
DOI: 10.2147/JHC.S488734.
Zhao Z, Jiang X, Wen S, Hao Y
Front Pharmacol. 2025; 15():1499269.
PMID: 39840082
PMC: 11747745.
DOI: 10.3389/fphar.2024.1499269.
Application of nanotechnology in the treatment of hepatocellular carcinoma.
Cai L, Du Y, Xiong H, Zheng H
Front Pharmacol. 2024; 15:1438819.
PMID: 39679376
PMC: 11637861.
DOI: 10.3389/fphar.2024.1438819.
FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study.
Lu Y, Yang Y, Ma D, Wang J, Hao F, Chen X
Front Immunol. 2024; 15:1471017.
PMID: 39660127
PMC: 11628521.
DOI: 10.3389/fimmu.2024.1471017.
The Efficacy and Safety of Bevacizumab Plus Anti-PD-1/PD-L1 Inhibitors in Combination with Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma.
Tang X, Chen J, Peng W, Yang Z, Hu L, Ye Z
Immunotargets Ther. 2024; 13:559-569.
PMID: 39478940
PMC: 11524013.
DOI: 10.2147/ITT.S478685.
Efficacy and safety of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk.
Liu Q, Zhang Y, Zhang J, Chen L, Yang Y, Liu Y
Front Oncol. 2024; 14:1374149.
PMID: 39077472
PMC: 11284057.
DOI: 10.3389/fonc.2024.1374149.
mA-mediated lnc-OXAR promotes oxaliplatin resistance by enhancing Ku70 stability in non-alcoholic steatohepatitis-related hepatocellular carcinoma.
Lin Z, Huang Z, Qiu J, Shi Y, Zuo D, Qiu Z
J Exp Clin Cancer Res. 2024; 43(1):206.
PMID: 39054531
PMC: 11271202.
DOI: 10.1186/s13046-024-03134-4.
Prognostic Value of Alpha-Fetoprotein in Unresectable Hepatocellular Carcinoma Treated with Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab.
Xiao Y, Chen W, Deng W, Zhu G, Xie J, Luo L
J Hepatocell Carcinoma. 2024; 11:1251-1263.
PMID: 38979083
PMC: 11228324.
DOI: 10.2147/JHC.S460922.
Association of serum AFP trajectories and hepatocellular carcinoma outcomes after hepatic arterial infusion chemotherapy: A longitudinal, multicenter study.
An C, Wei R, Yao W, Han W, Li W, Shi G
Cancer Med. 2024; 13(11):e7319.
PMID: 38819606
PMC: 11141330.
DOI: 10.1002/cam4.7319.
Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma.
Lin Z, Hu X, Chen D, Huang D, Zou X, Zhong H
World J Gastroenterol. 2024; 30(17):2321-2331.
PMID: 38813052
PMC: 11130568.
DOI: 10.3748/wjg.v30.i17.2321.
Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
Fu S, Xu Y, Mao Y, He M, Chen Z, Huang S
Cancer Med. 2024; 13(9):e7105.
PMID: 38686567
PMC: 11058683.
DOI: 10.1002/cam4.7105.
Efficacy and Safety of Conversion Surgery for Advanced Hepatocellular Carcinoma After Hepatic Arterial Infusion Chemotherapy.
Li W, Zheng Z, Wang J, Wu T, Wang J, Pan Y
J Hepatocell Carcinoma. 2024; 11:463-475.
PMID: 38463545
PMC: 10922940.
DOI: 10.2147/JHC.S447387.
Techniques and status of hepatic arterial infusion chemotherapy for primary hepatobiliary cancers.
Zheng K, Wang X
Ther Adv Med Oncol. 2024; 16:17588359231225040.
PMID: 38282664
PMC: 10822083.
DOI: 10.1177/17588359231225040.
Systemic Inflammation Score Using Pretherapeutic Inflammatory Markers to Predict Prognosis for Hepatocellular Carcinoma Patients After Hepatic Arterial Infusion Chemotherapy.
Wu T, Zheng Z, Wang J, He M, Wang J, Pan Y
J Hepatocell Carcinoma. 2023; 10:2133-2145.
PMID: 38058386
PMC: 10697146.
DOI: 10.2147/JHC.S437329.
Tenofovir versus Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma After FOLFOX-Hepatic Arterial Infusion Chemotherapy.
Zheng Z, Wang J, Wu T, He M, Wang J, Pan Y
J Hepatocell Carcinoma. 2023; 10:2117-2132.
PMID: 38053944
PMC: 10695128.
DOI: 10.2147/JHC.S436062.
The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma.
Ding Y, Wang S, Qiu Z, Zhu C, Wang Y, Zhao S
Front Immunol. 2023; 14:1284937.
PMID: 38022559
PMC: 10644007.
DOI: 10.3389/fimmu.2023.1284937.
Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab.
Xiao Y, Zhu G, Xie J, Luo L, Deng W, Lin L
J Hepatocell Carcinoma. 2023; 10:2049-2058.
PMID: 37965074
PMC: 10642375.
DOI: 10.2147/JHC.S432134.
